Skip to main content
HLB Therapeutics Co.,Ltd. logo

HLB Therapeutics Co.,Ltd. — Investor Relations & Filings

Ticker · 115450 ISIN · KR7115450009 KO Manufacturing
Open in API
Filings indexed 444 across all filing types
Latest filing 2023-08-16 Capital/Financing Update
Country KR South Korea
Listing KO 115450

About HLB Therapeutics Co.,Ltd.

https://hlbtherapeutics.co.kr/en/

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's clinical-stage pipeline focuses on addressing unmet medical needs in ophthalmology and oncology. Key development programs include RGN-259, a therapeutic agent for Dry Eye Disease and Neurotrophic Keratopathy, and OKN-007 for the treatment of Glioblastoma Multiforme. Additionally, the company is advancing a Natural Killer (NK) cell therapy through late-stage clinical trials to provide new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
전환사채(해외전환사채포함)발행후만기전사채취득(제13회차)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from HLB Therapeutics regarding the 'Acquisition of Convertible Bonds before Maturity'. It details the specific terms of the bond (13th series), the acquisition amount, the reason for acquisition (cancellation), and the source of funds. This falls under capital structure and financing updates, specifically related to debt management and capital changes. Given the specific nature of bond buybacks/cancellations, it fits best under the 'Capital/Financing Update' category.
2023-08-16 Korean
전환가액의조정(제13, 14회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from HLB Therapeutics regarding the adjustment of conversion prices for convertible bonds (13th and 14th series). It details the specific price changes, the calculation methodology based on market price fluctuations, and the impact on the number of convertible shares. This type of disclosure is a standard capital structure update related to financing instruments, which falls under the 'Capital/Financing Update' category.
2023-08-16 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for HLB Therapeutics Co., Ltd. for the period ending June 30, 2023. It contains detailed financial information, business descriptions, and management disclosures required by the Financial Supervisory Service (FSS) and Korea Exchange (KRX). As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. H1 2023
2023-08-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by a major shareholder and their special related parties, including the purpose of holding (influence on management) and specific transaction details (market purchases). This fits the definition of a 'Major Shareholding Notification' (MRQ).
2023-07-31 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Ahn, Ki Hong) of HLB Therapeutics. This type of filing is a standard regulatory requirement for reporting insider transactions (director's dealings) in South Korea. It details the acquisition of shares by an executive, which falls under the 'Director's Dealing' category.
2023-07-28 Korean
기타경영사항(자율공시)(소규모합병 승인 이사회결의(주주총회 갈음) 결과 보고)
AGM Information Classification · 100% confidence The document is a regulatory filing from HLB Therapeutics regarding the approval of a small-scale merger with its subsidiary, SJ Pharm. It details the board resolution, merger ratio, and the results of the shareholder opposition period. Since this document describes a specific corporate merger activity (M&A) and is not a general announcement of a report, it falls under the M&A Activity category.
2023-07-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.